The content on this site is intended for healthcare professionals only
First-line nivolumab + ipilimumab + chemo in patients with advanced NSCLC and brain metastases: Results From CheckMate 9LA
Trastuzumab deruxtecan vs trastuzumab emtansine in patients with HER2+ metastatic breast cancer
ESMO 2021: PARPi data and their role in mono/combination therapies
ESMO 2021: Breast cancer roundup
[Vic-]trastuzumab duocarmazine shows improved PFS in pre-treated HER2+ locally advanced or metastatic breast cancer
![[Vic-]trastuzumab duocarmazine shows improved PFS in pre-treated HER2+ locally advanced or metastatic breast cancer ( Dr Cristina Saura - Vall d’Hebron University Hospital, Barcelona, Spain )](https://cdn.ecancer.org/42950-m.jpg)
Acetylsalicylic acid added to atezolizumab bevacizumab combo does not improve efficacy in ovarian, fallopian, peritoneal cancer
Drug combination shows promise in treatment-resistant advanced ovarian cancer
Welcome to APCCC 2021
IMpower010: A Phase 3 study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC
ESMO 2021 Roundup
Melflufen and dexamethasone vs pomalidomide and dexamethasone in relapsed refractory multiple myeloma
OncoAlert and ecancer - ESMO 2021 Day 5
